Browse IGFBP2

Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00219 Insulin-like growth factor binding protein
PF00086 Thyroglobulin type-1 repeat
Function

Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001558 regulation of cell growth
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0007565 female pregnancy
GO:0007568 aging
GO:0007584 response to nutrient
GO:0009612 response to mechanical stimulus
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031667 response to nutrient levels
GO:0031960 response to corticosteroid
GO:0032355 response to estradiol
GO:0032526 response to retinoic acid
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042493 response to drug
GO:0043567 regulation of insulin-like growth factor receptor signaling pathway
GO:0043627 response to estrogen
GO:0044706 multi-multicellular organism process
GO:0045785 positive regulation of cell adhesion
GO:0046006 regulation of activated T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048545 response to steroid hormone
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051384 response to glucocorticoid
GO:0060070 canonical Wnt signaling pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function GO:0005520 insulin-like growth factor binding
GO:0019838 growth factor binding
GO:0031994 insulin-like growth factor I binding
GO:0031995 insulin-like growth factor II binding
Cellular Component GO:0016324 apical plasma membrane
GO:0045177 apical part of cell
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-392499: Metabolism of proteins
R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IGFBP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IGFBP2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29721393GlioblastomaInhibit immunity; Candidate for immunotherapy targetWe further selected specific immunologic related gene sets and found IGFBP2 predominated immunosuppressive activities in GBM. We discovered that IGFBP2 was correlated with CHI3L1, TNFRSF1A, LGALS1, TIMP1, VEGFA, ANXA1 and LGALS3, which were classic immunosuppressive biomarkers. Higher IGFBP2 expression predicted unfavorable survival for patients with GBM. IGFBP2 is a potential immunotherapeutic target for GBM in future clinical trials.
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IGFBP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IGFBP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6170.433
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.4160.423
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6920.768
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8830.0809
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6990.689
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1160.613
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1720.766
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3890.815
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0690.97
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.640.433
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1570.953
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3230.135
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IGFBP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47028.6-28.60.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IGFBP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IGFBP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IGFBP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IGFBP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IGFBP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IGFBP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIGFBP2
Nameinsulin-like growth factor binding protein 2, 36kDa
Aliases IBP2; insulin-like growth factor binding protein 2 (36kD); IGF-BP53; IGF-binding protein 2; IGFBP-2; IBP-2; ......
Chromosomal Location2q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IGFBP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.